The discovery of new diseases is frequent and alarming. The health care sector is in continuous need of new drugs to counter these diseases. Drug companies face financial risks and significant costs in drug R&D, which may end in failure. The risks and costs create dilemmas for the drug makers; firms charge high prices for their products to make profits and recover all costs incurred from their failures. Regarding demand, affordability is an issue, as prices can be out of reach for most patients, thus undermining the objective of the ICESCR, which guarantees the rights of the public to equal access to the highest attainable standard of physical and mental health. The clash between consumers and producers in terms of drug pricing makes a good case for government intervention to increase total social welfare and establish a balanced approach to pricing regimes. This study assesses the impact of drug patent extensions and their constraints with an aim to maximise total social welfare.
Our 2020 Annual Conference was scheduled to be held at the University of Wrocław in Poland on July 9-11, 2020.
Due to the COVID-19 pandemic, the ICON·S Executive Committee has decided to postpone our 2020 Conference to 2021. Our next Annual Conference will take place from July 8-10, 2021, in Wrocław, Poland.
Procedural details regarding the organization of the 2021 Conference will follow in the months ahead.Join ICON•S